Journals in Pharmacology

Elsevier's Pharmacology collection studies how drugs interact with biological systems to improve health and treat disease. It covers pharmacodynamics, exploring drug effects on biology, and pharmacokinetics, studying how the body affects drugs. Branches like Pharmacogenetics. Essential for pharmacologists, this collection offers invaluable insights into drug interactions, efficacy, and safety, crucial for advancing drug development and improving patient outcomes.

Books Journals

ASPET Discovery

ISSN: 3050-5674

This open access journal publishes a range of article types, including original research articles, minireviews, and viewpoints that address all areas of pharmacology and experimental therapeutics. These areas include, but are not limited to, topics on interactions of chemicals with biological systems; drug absorption, distribution, metabolism and disposition; drug delivery; mechanisms of drug actions; pharmacokinetics and pharmacodynamics; toxicology and adverse drug responses; behavioral pharmacology and drugs of abuse; and preclinical, translational, and clinical pharmacology. The journal will cover all types of therapeutic indications, such as cardiovascular, infectious, neurological, and cancerous; all forms of therapeutics, such as small molecules, biologics, and cells; and all research approaches, such as molecular, cellular, and systems pharmacology.

Antiviral Research

ISSN: 0166-3542
5 Year impact factor: 5
Impact factor: 4.5

Antiviral Research aims to publish manuscripts in the field of prevention and treatment of viral diseases in humans and vertebrate animals, and encourages authors to the submit manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases. The journal is an Official Publication of the International Society for Antiviral Research. The types of papers published in Antiviral Research includes original research reports, short communications, commentaries and invited review* articles on the control of viral infections in humans. The journal’s scope encompasses:antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action.identification and validation of new drug targets;laboratory animal models of viral diseases for antiviral efficacy testing;evolution of drug-resistant viruses and the development of effective counter measures;pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses;assessments of drug safety;new or improved vaccines against viral infections of humans; the prevention and treatment of viral diseases of vertebrate animals, and reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis that must be clearly described in the manuscript.Antiviral Research journal does not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species.We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We discourage the submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]."ISAR members Authors who are ISAR members are encouraged to contact ISAR after their paper has been accepted for publication in order to benefit from their published work being highlighted in ISAR postings on their social media platforms (further details on this will be given in the AVR acceptance letter). *Antiviral Research journal has started a new initiative to publish at least two thematic special issues per year, containing invited reviews in addition to the ad hoc invitations to experts in the areas within the scope of the journal.

Artificial Intelligence in the Life Sciences

ISSN: 2667-3185

Providing a scientific forum for practical applications and theoretical advances of Artificial Intelligence (AI) in the life sciences and related disciplines including (but not restricted to):New AI methods for life science researchAdaptation of existing AI concepts for life science applicationsApplication of AI approaches in: Molecular and systems biologyPopulation and disease geneticsBio- and cheminformaticsMedicinal chemistry, chemical biology, and drug discoveryMedical researchPublications are required to contain substantial AI and life science components. Clinical studies reporting routine diagnostic efforts hall outside the scope of AILSCI.Background: Artificial Intelligence originates from computer science and covers a wide range of approaches intended to enhance the ability of machines to make data-driven decisions and accurate predictions of events. In many scientific fields, AI is being increasingly considered and integrated, especially in the context of Big Data. Given their complexity and highly interdisciplinary nature, the life sciences provide ample opportunities for AI to impact R&D efforts in a variety of ways.Key words: Artificial Intelligence; Life Sciences; Drug Discovery; Bio- and Cheminformatics, Machine Learning; Machine Intelligence; Deep Learning; Data Mining; Big Data.

Biochemical Pharmacology

ISSN: 0006-2952
5 Year impact factor: 5.2
Impact factor: 5.3

Biochemical Pharmacology publishes original research findings and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complementary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study.The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature.Original research submissions must contain:A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulators of receptors, enzymes and signaling pathways.Justification must also be provided for the selection of the statistical tests employed as they relate to the experimental design.It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series.Manuscripts that fail to meet these criteria will be subject to rejection without peer-review.US National Institutes of Health (NIH) voluntary posting ("Public Access") policy:Biochemical Pharmacology and Elsevier facilitate the author's response to the NIH Public Access Policy.

Biomedicine & Pharmacotherapy

ISSN: 0753-3322
5 Year impact factor: 6.8
Impact factor: 6.9

Biomedicine & Pharmacotherapy is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology.The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers

Cellular Signalling

ISSN: 0898-6568
5 Year impact factor: 4.4
Impact factor: 4.4

Cellular Signalling publishes original research describing fundamental and clinical findings on the mechanisms, actions and structural components of cellular signalling systems in vitro and in vivo.Cellular Signalling aims at full length research papers defining signalling systems ranging from microorganisms to cells, tissues and higher organisms.Cellular Signalling strives to offer a fair and fast peer-review process with a single round of revisions. Reviews are by invitation-only. Short Reports are not accepted.

Clinical Microbiology Newsletter

ISSN: 0196-4399

Clinical Microbiology Newsletter is published bi-monthly to to provide consistent educational features and to keep pace with advances in the fast-moving field of Clinical Microbiology.Clinical Microbiology Newsletter aims to provide articles to enable you to streamline procedures and improve results. It publishes reviews on infectious disease pathogens, reports on changes that affect your work, including articles on new diagnostic techniques, regulatory and guideline changes, and challenging diagnostic dogmas, clinical cases focused on diagnostic approaches for both common and uncommon pathogens.The journal publishes three types of articles:Mini-reviews Case presentationsMicrobe SnapshotsThese articles cover topics including:Minireviews on the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of infectious diseases,Practical articles on common and contemporary laboratory techniques,Indispensable updates on important clinical problems that impact the clinical laboratory,Editorials and opinions on controversial issues in laboratory medicine,Case-based articles focused on diagnostic approaches for infectious pathogens,Snapshots highlighting specific infectious pathogens,Helpful tips on improving the laboratory workplace.

Clinical Therapeutics

ISSN: 0149-2918
5 Year impact factor: 3
Impact factor: 3.2

The International Peer-Reviewed Journal of Drug TherapyClinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.Published articles range from pivotal studies exploring new chemical entities in large, multicenter trials to those exploring repurposing of marketed agents. Additionally, pilot studies; reports that assess drug safety and tolera-bility in all phases of development; new routes of administration and new formulations; pharmacokinetic, bio-availability, and biosimilarity; and changes in practice guidelines and standards, are all of interest for publication. Clinical Therapeutics also understands the importance of strengthening the body of evidence surrounding particular agents through the publication of replication studies, negative trials, and failed trials.Beyond the clinic, we seek reports that examine the real-world implications of therapeutics such as comparative effectiveness and pharmacoeconomics studies as well as work that has implications for health policy. Commentaries, which include perspectives and contemporary issues, are sought to offer a balance of viewpoints and scholarly opinion on a broad array of drug-related topics. Case reports, which remain a vital part of our mission, offer clinically valuable lessons. All manuscripts are peer reviewed by independent clinicians or scientists for clinical relevance, technical accuracy, methodological rigor, clarity, and objectivity using a blind review process.In addition to feature articles published monthly, each issue of Clinical Therapeutics features a specific theme section dedicated to an annual update of a specific topic area. A special guest editor will comprise each update with reviews, commentaries, and original research highlighting what's new or controversial in the topical specialty. Authors are invited to submit manuscripts for consideration in the topic updates, identifying submissions as such in their cover letters. Submissions not selected for the updates will be considered for general publication. Submit your manuscript at https://www.editorialmanager.com/clinther.

Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology

ISSN: 1095-6433
5 Year impact factor: 2.2
Impact factor: 2.1

Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology.Part A: Molecular and Integrative Physiology (CBPA), focuses on physiological systems, including behavior, circulation, development, excretion, ion regulation, endocrinology, locomotory, nervous, nutrition, respiration, and thermal biology. Most studies address regulatory mechanisms and span multiple levels of biological organization.All four CBP journals support and follow the editorial direction from all the major societies in the field:Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB)American Physiological Society (APS)Canadian Society of Zoologists (CSZ)Deutsche Zoologische Gesellschaft (DZG)European Society of Comparative Physiology and Biochemistry (ESCPB)Japanese Society for Comparative Physiology and Biochemistry (JSCPB)South American Society for Comparative Physiology and Biochemistry (SASCPB)Societe de Physiologie (SDP)Society for Experimental Biology (SEB)Society for Integrative & Comparative Biology (SICB)Benefits to authorsCBP journals are focused on promoting the authors and the work published in the journal:All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field.Availability: contact the Editor-in-Chief for any questions you may have.The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library.Publication is free to authors (no color or page charges).Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here.Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect.Please click here for more information on more general author services.Other CBP journals Part B (CBPB): Biochemistry & Molecular Biology Part C (CBPC): Toxicology & Pharmacology Part D (CBPD): Genomics & Proteomics

Comparative Biochemistry and Physiology - Part C: Toxicology & Pharmacology

ISSN: 1532-0456
5 Year impact factor: 3.9
Impact factor: 3.9

Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology.Part C: Toxicology and Pharmacology (CBPC), focuses on toxicological mechanisms at different levels of organization, primarily chemical and drug action, biotransformation of xenobiotics, endocrine disruptors, nanoparticles, pharmaceuticals, and natural products chemistry. Most studies employ a molecular approach in combination with observations of higher levels of organization to assess the mechanism by which xenobiotics affect physiology. Analytical verification of exposure concentrations is strongly recommended for manuscripts reporting toxicological studies.All four CBP journals support and follow the editorial direction from all the major societies in the field:Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB)American Physiological Society (APS)Canadian Society of Zoologists (CSZ)Deutsche Zoologische Gesellschaft (DZG)European Society of Comparative Physiology and Biochemistry (ESCPB)Japanese Society for Comparative Physiology and Biochemistry (JSCPB)South American Society for Comparative Physiology and Biochemistry (SASCPB)Societe de Physiologie (SDP)Society for Experimental Biology (SEB)Society for Integrative & Comparative Biology (SICB)Benefits to authorsCBP journals are focused on promoting the authors and the work published in the journal:All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field.Availability: contact the Editor-in-Chief for any questions you may have.The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library.Publication is free to authors (no color or page charges).Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here.Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect.Please click here for more information on more general author services.Other CBP journals Part A (CBPA): Molecular & Integrative Physiology Part B (CBPB): Biochemistry & Molecular Biology Part D (CBPD): Genomics & Proteomics

Related subjects

Biochemical pharmacology

Cardiovascular pharmacology

Clinical pharmacology therapeutics

Clinical trials

Drug adverse reactions and interactions

Endocrine exocrine pharmacology

Ethnopharmacology

Gastrointestinal pharmacology

Immunopharmacology pharmacology

Molecular pharmacology

Neoplastic cancer pharmacology

Pharmacokinetics pharmacodynamics

Pharmacology general

Principles of pharmacology

Psychoneuropharmacology

Pulmonary pharmacology

Renal and electrolyte pharmacology

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health